Industries de la santé
Anagenesis Biotechnologies and Ksilink announce a collaborative research agreement to apply stem-cell derived disease models of Duchenne Muscular Dystrophy to small molecule therapies discovery and development
04 Février 2016
Strasbourg, France, February 2nd, 2016. Anagenesis Biotechnologies and Ksilink announced today the signature of a collaborative research agreement. Each partner will apply its expertise to the discovery and development of small molecule therapies for Duchenne Muscular Dystrophy (DMD) thanks to unique stem-cell derived disease models. |A one-of-a-kind collaboration to develop new therapies...
Plus d'articles...
- Strategic Additions in Key Areas Will Support Later Stage Clinical Trials for Iomab-B and Actimab-A
- I.Ceram : activité 2015 conforme aux prévisions : 1,7 ME
- Edward Jordan rejoint DBV Technologies au poste de Senior Vice-Président Opérations Commerciales pour l'Amérique du Nord
- Onxeo annonce l'évolution et le renforcement de son Conseil d'Administration